Test Price
3,500 AEDโ Home Collection Available
Comprehensive Hereditary Cancer Panel (190 Genes) Test in UAE
Executive Summary & Core Metrics
Our Comprehensive Hereditary Cancer Panel delivers 99.9% diagnostic sensitivity through ISO-accredited Next Generation Sequencing (NGS). The test evaluates 190 genes associated with inherited cancer syndromes, providing actionable risk stratification for personalized surveillance and prevention planning. We offer premium logistics including VIP mobile phlebotomy with temperature-controlled cold-chain home collection (available daily 8 AMโ11 PM) and telephonic post-test clinical guidance by a qualified genetics professional. Direct billing verification is available via WhatsApp at +971 54 548 8731. Pre-test mandatory: A completed Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) must be submitted before sample collection.
- Accuracy: >99.9% analytical sensitivity and specificity.
- Coverage: 190 cancer-susceptibility genes in a single assay.
- Turnaround: Results within 4 weeks from sample receipt.
- Support: Post-test telephonic genetic counselling included.
Test Overview & Methodology
The panel targets the coding regions and flanking intronic sequences of 190 key genes implicated in hereditary cancer predisposition (e.g., BRCA1, BRCA2, MLH1, MSH2, TP53, APC). DNA extracted from peripheral blood undergoes enrichment via hybrid capture followed by paired-end sequencing on an Illumina platform. Variant calling, annotation, and classification adhere to ACMG/AMP guidelines. The test detects single nucleotide variants, small insertions/deletions, and copy number variations (CNVs) in the covered regions.
| Feature | Our NGS Panel (190 Genes) | Single-Gene Testing |
|---|---|---|
| Precision | >99.9% analytical sensitivity | Similar per gene, limited scope |
| Multi-Gene Coverage | 190 genes in one assay | 1 gene at a time โ cumulative cost higher |
| Turnaround Time | 4 weeks (comprehensive) | 2โ4 weeks per gene, sequential |
Physician Insight & Safety Protocols
โGenetic testing for hereditary cancer risk provides valuable information but is not a diagnostic endpoint. A positive finding must be interpreted alongside personal and family history; a negative result does not eliminate all susceptibility. Always consult your oncologist or a genetic counsellor to integrate results into a personalized surveillance plan.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Medication Caution: Do not discontinue prescribed medication without consulting your doctor. Certain drugs may affect DNA quality or interact with test interpretation.
Exclusion Criteria & Safety Precautions
Important safety and regulatory considerations under the UAE medical liability framework (Federal Decree-Law No. 4 of 2016 on Medical Liability):
- Testing for individuals under 18 years requires valid legal guardian consent and clinical justification per the law.
- Severe anemia (hematocrit <20%) may compromise blood sample quality for NGS.
- Acute systemic infection or high-dose steroid therapy can temporarily affect DNA integrity โ discuss timing with your physician.
- Emergency Red Flag: If you experience sudden severe pain, bleeding, or signs of anaphylaxis after sample collection, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What genes are covered in the 190โgene panel?
The panel covers 190 key cancer-susceptibility genes including BRCA1, BRCA2, MLH1, MSH2, TP53, APC, and others, sequenced with high-fidelity NGS technology.
2. How long does it take to receive results?
Standard turnaround time is 4 weeks from the arrival of the sample and completed Form 27 at our ISO-accredited laboratory.
3. Do you provide post-test genetic counselling?
Yes, we offer telephonic clinical guidance with a qualified genetic counsellor to help interpret your results and suggest next steps.
UAE Regulatory & Data Privacy Adherence
Compliance with UAE data protection and health information laws: This test is performed at DNA Labs UAE under DHA Facility License No. 1143. All personal data and genetic information are handled in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No genetic data is shared with third parties without explicit written consent. Sample handling and processing follow ISO 15189 standards for medical laboratories.
Clinical & Logistical Metadata
| Test Name | Comprehensive Hereditary Cancer Panel (190 Genes) |
| Price (AED) | 2,800 |
| Turnaround Time | 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) โ VIP mobile phlebotomy & temperature-controlled cold-chain home collection available daily 8 AMโ11 PM |
| Methodology Used | Next Generation Sequencing (NGS) โ Hybrid capture, Illumina platform |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 88866-5 (Hereditary cancer panel) |
| DHA Facility License & Laboratory Address | DNA Labs UAE โ License No. 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians